Industry
Drug Manufacturers - Specialty & Generic
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Loading...
Open
1.18
Mkt cap
3.9M
Volume
80K
High
1.19
P/E Ratio
-0.33
52-wk high
4.94
Low
1.15
Div yield
N/A
52-wk low
1.03
Portfolio Pulse from Avi Kapoor
October 30, 2024 | 10:16 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 7:52 am
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 6:30 pm
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
October 29, 2024 | 2:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 10:56 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.